Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2478207 | 0.73 | CYP11B1 (0.48) | CHRNB4CHRNA3 | |
| SCHEMBL31001734 | 0.73 | CYP11B1 (0.48) | CHRNB4CHRNA3 | |
| SCHEMBL1157101 | 0.73 | — | — | |
| SCHEMBL11486733 | 0.70 | SIGMAR1 (0.31) | SIGMAR1CHRNB4CHRNA3 | |
| SCHEMBL4538757 | 0.70 | — | — | |
| SCHEMBL19075927 | 0.70 | CYP11B1 (0.42) | SIGMAR1CHRNB4CHRNA3 | |
| SCHEMBL4254737 | 0.69 | STS (0.35) | SIGMAR1CHRNB2CHRNA4 | |
| SCHEMBL31065699 | 0.69 | STS (0.38) | SIGMAR1CHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL1653598 | 0.69 | AOC1 (0.31) | SIGMAR1 | |
| SCHEMBL2655460 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043435-A1 | TYK-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2024-02-08 | — | — | US | claimed |
| WO-2023079294-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-05-11 | — | — | WO | claimed |
| US-10246429-B2 | Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2019-04-02 | — | — | US | claimed |
| US-20180222876-A1 | VINYL FLUORIDE CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2018-08-09 | — | — | US | claimed |
| US-20240043435-A1 | TYK-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2024-02-08 | — | — | US | disclosed |
| WO-2023079294-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-05-11 | — | — | WO | disclosed |
| US-10604536-B2 | Substituted cyclopropanes as PDE-10 inhibitors | Sunovion Pharamaceuticals Inc. (US) | 2020-03-31 | — | — | US | disclosed |
| US-10246429-B2 | Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2019-04-02 | — | — | US | disclosed |
| EP-2861596-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20180258104-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharamaceuticals Inc. | 2018-09-13 | — | — | US | disclosed |
| US-20180222876-A1 | VINYL FLUORIDE CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2018-08-09 | — | — | US | disclosed |
| US-9994590-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20130324579-A1 | NOVEL PYRAZOLE AND IMIDAZOLE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-12-05 | — | — | US | disclosed |
| EP-2638008-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-12 | — | — | US | disclosed |
| WO-2012110986-A1 | NOVEL PYRAZOLE AND IMIDAZOLE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-08-23 | — | — | WO | disclosed |
| WO-2012063207-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-05-18 | — | — | WO | disclosed |
| US-8153634-B2 | Carbinol derivatives having cyclic linker | KOWA COMPANY, LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| EP-2281817-A1 | SUBSTITUTED CARBINOL COMPOUND HAVING CYCLIC LINKER | Kowa Company, Ltd. (JP) | 2011-02-09 | — | — | EP | disclosed |
| US-20100048610-A1 | CARBINOL DERIVATIVES HAVING CYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222876-A1 | VINYL FLUORIDE CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | SIGMAR1 3495/4885CHRNB4 91/4885CHRNA3 139/4885 |
| US-10246429-B2 | Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use | BACE1, BACE2, APP | SIGMAR1 3495/4885CHRNB4 91/4885CHRNA3 139/4885 |
| US-20130237525-A1 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | SIGMAR1 85/4885CHRNB4 365/4885CHRNA3 214/4885 |
| US-20240043435-A1 | TYK-2 INHIBITOR | TYK2, IRAK2, PTK2B | SIGMAR1 4773/4885CHRNB4 3818/4885CHRNA3 3264/4885 |
| US-20100048610-A1 | CARBINOL DERIVATIVES HAVING CYCLIC LINKER | NR1H2, NR1H3, LDLR | SIGMAR1 2915/4885CHRNB4 988/4885CHRNA3 807/4885 |
| US-20180258104-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | SIGMAR1 1481/4885CHRNB4 2583/4885CHRNA3 739/4885 |
| US-10604536-B2 | Substituted cyclopropanes as PDE-10 inhibitors | PDE10A, PDE2A, PDE3A | SIGMAR1 4129/4885CHRNB4 790/4885CHRNA3 615/4885 |
| US-20130324579-A1 | NOVEL PYRAZOLE AND IMIDAZOLE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | SIGMAR1 104/4885CHRNB4 353/4885CHRNA3 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.